CR20110368A - Compuestos de quinazolina sustituidos - Google Patents

Compuestos de quinazolina sustituidos

Info

Publication number
CR20110368A
CR20110368A CR20110368A CR20110368A CR20110368A CR 20110368 A CR20110368 A CR 20110368A CR 20110368 A CR20110368 A CR 20110368A CR 20110368 A CR20110368 A CR 20110368A CR 20110368 A CR20110368 A CR 20110368A
Authority
CR
Costa Rica
Prior art keywords
methods
substituted quinazoline
quinazoline compounds
compounds
kinase
Prior art date
Application number
CR20110368A
Other languages
English (en)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110368(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of CR20110368A publication Critical patent/CR20110368A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

La invención se dirige a ciertos compuestos novedosos, métodos para producirlos y métodos para tratar o mejorar un trastorno mediado por cinasa. Más particularmente, esta invención se dirige un compuestos de quinazolina sustituidos útiles como inhibidores de cinasa selectivos, métodos para producir tales compuestos y métodos para tratar o mejorar un trastorno mediado por cinasa.
CR20110368A 2008-12-29 2011-06-27 Compuestos de quinazolina sustituidos CR20110368A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29

Publications (1)

Publication Number Publication Date
CR20110368A true CR20110368A (es) 2011-12-02

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110368A CR20110368A (es) 2008-12-29 2011-06-27 Compuestos de quinazolina sustituidos

Country Status (23)

Country Link
US (1) US8389530B2 (es)
EP (1) EP2381943A1 (es)
JP (1) JP2012514020A (es)
KR (1) KR20110120878A (es)
CN (1) CN102333533A (es)
AU (1) AU2009334869A1 (es)
BR (1) BRPI0924067A2 (es)
CA (1) CA2748319A1 (es)
CO (1) CO6390105A2 (es)
CR (1) CR20110368A (es)
DO (1) DOP2011000209A (es)
EA (1) EA019110B1 (es)
EC (1) ECSP11011204A (es)
IL (1) IL213742A0 (es)
MA (1) MA32968B1 (es)
MX (1) MX2011007064A (es)
NI (1) NI201100134A (es)
NZ (1) NZ593949A (es)
PE (1) PE20120424A1 (es)
SG (1) SG172415A1 (es)
TN (1) TN2011000319A1 (es)
WO (1) WO2010076238A1 (es)
ZA (1) ZA201104777B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
PL2872491T3 (pl) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitory receptora czynnika wzrostu fibroblastów
CN110028491B (zh) 2013-10-25 2022-02-11 缆图药品公司 纤维母细胞生长因子受体抑制剂
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
EA201791304A1 (ru) 2014-12-24 2017-12-29 Джилид Сайэнс, Инк. Производные изохинолина для лечения вич
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003140A (es) * 1999-11-22 2002-09-30 Warner Lambert Co Quinazolinas y su uso para la inhibicion de las enzimas cinasa dependientes del ciclin.
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EP1680122A1 (en) 2003-10-16 2006-07-19 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for the treatment of cancer
EP1809614B1 (en) 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
WO2006024034A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2006227628A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
US7906522B2 (en) * 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
MX2007008848A (es) 2005-06-08 2008-04-16 Targegen Inc Metodos y composiciones para el tratamiento de desordenes oculares.
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
EP2125755A2 (en) * 2006-12-22 2009-12-02 Novartis Ag Quinazolines for pdk1 inhibition

Also Published As

Publication number Publication date
ECSP11011204A (es) 2011-10-31
CN102333533A (zh) 2012-01-25
DOP2011000209A (es) 2011-09-30
CO6390105A2 (es) 2012-02-29
US20120004210A1 (en) 2012-01-05
AU2009334869A1 (en) 2011-07-14
NZ593949A (en) 2013-08-30
EP2381943A1 (en) 2011-11-02
PE20120424A1 (es) 2012-05-04
NI201100134A (es) 2012-03-06
MA32968B1 (fr) 2012-01-02
ZA201104777B (en) 2012-03-28
BRPI0924067A2 (pt) 2016-01-26
US8389530B2 (en) 2013-03-05
TN2011000319A1 (en) 2012-12-17
KR20110120878A (ko) 2011-11-04
EA201101012A1 (ru) 2012-01-30
AU2009334869A2 (en) 2011-09-29
WO2010076238A1 (en) 2010-07-08
MX2011007064A (es) 2012-01-20
JP2012514020A (ja) 2012-06-21
CA2748319A1 (en) 2010-07-08
IL213742A0 (en) 2011-07-31
SG172415A1 (en) 2011-07-28
EA019110B1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
CR20110368A (es) Compuestos de quinazolina sustituidos
CR20110386A (es) 1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa
CR20110103A (es) Heteroarilos sustituidos
WO2010129053A3 (en) Egfr inhibitors and methods of treating disorders
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
NZ598516A (en) Quinazolines as potassium ion channel inhibitors
CR10995A (es) Inhibidores de la actividad de akt
ECSP12011982A (es) Aminopirimidinas como inhibidores de syk
EA201171367A1 (ru) Винилиндазолильные соединения
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
MX2010005395A (es) Metodo para tratar artritis.
UY32291A (es) Inhibidores de quinasa con perfiles de seguridad cyp mejorados
EA201170831A1 (ru) Аминопиразольное соединение
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
UY37017A (es) Inhibidores aza-bencimidazol de pad4
IN2014CN04050A (es)
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)